Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Diffuse Large B-Cell Lymphoma Refractory Clinical Trial

Official title:
A Phase II Study of the Efficacy and Safety of Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed Diffuse Large B-cell Lymphoma

Status Active, not recruiting

Clinical Trial Summary

This study is to evaluate the efficacy and safety of Lenalidomide plus ICE in the treatment of Refractory and Relapsed DLBCL patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Diffuse Large B-Cell Lymphoma Refractory
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse

Clinical Trial Details

NCT number	NCT03367143
Study type	Interventional
Source	Ruijin Hospital
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 2016
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02594163` - Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma	Phase 2
Active, not recruiting	`NCT04703686` - Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	Phase 2
Completed	`NCT01805557` - Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.	Phase 2/Phase 3
Completed	`NCT03589469` - Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Phase 2
Not yet recruiting	`NCT06271057` - Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse	Phase 2